Patients harbouring IRAK1 variants exhibited more severe clinical manifestations, including diffuse cutaneous lesions and interstitial lung disease, consistent with earlier findings linking IRAK1 polymorphisms to enhanced disease activity and fibrosis pathways in SSc [22,23]. This evidence concerns the gene IRAK1 and systemic sclerosis.